NCI Designated. Illinois Powered. Cancer Center at Illinoi

Big News. Today the Cancer Center at Illinois becomes the 8th NCI Designated Basic Cancer Center.

www.cancer.gov/research/inf...

The deadline to submit your late-breaking abstracts for #ENDO2026 is Tuesday, April 21! This is your opportunity to connect with leading investigators, gain valuable exposure for your work, and help advance the science that drives better patient care: bit.ly/4sF4zAY

ENDO 2026: Late-Breaking Abstracts Now Open | Submit your late-breaking abstract for presentation at ENDO by Tuesday, April 21 at 1:00 PM ET: bit.ly/4sF4zAY #ENDO2026 #endocrinology #hormonescience

Register now for an amazing menu of endocine-related science and clinical practice! Early bird rate is ending soon! #ENDO2026

ENDO 2026 Early Registration Is Now Open | Join us in Chicago, IL, US for thought-provoking sessions and discussions on the latest in hormone health and science. Secure the lowest rates (bit.ly/4awLVUd) and watch our video (bit.ly/4kByPcY) #ENDO2026 #endocrinology #EndoSky

ENDO2026 has an amazing lineup! The best of basic, translational and clinical sciences. Don't miss out!

Tumors grew faster and were more resistant to immune checkpoint blockade in mice lacking macrophage-ABCA1. ABCA1 represents an exciting new target to improve immunotherapies!

ABCA1 ↑s macrophage infiltration into tumors, ↓s angiogenic potential, ↓s efferocytosis, and ↑s support of T cell expansion and cytotoxic activity.

Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells Cholesterol efflux protein ABCA1 shifts macrophages to being anticancer, highlighting its potential use as a therapeutic target.

New paper from the Nelson Lab! ABCA1 activity re-educates macrophages to being anti-cancer.

Science Advances Paper here: www.science.org/doi/10.1126/...

ENDO 2026 Travel Grants Expanded | To support our research and early career communities, we are thrilled to announce a one-year expansion of our ENDO 2026 travel grant programs. This expansion will provide heightened support to more researchers. Learn more: https://bit.ly/4pvLqPA #ENDO2026

ENDO 2026 Plenary Lineup We are excited to announce the ENDO 2026 Plenaries! Taking place June 13-16, 2026, in Chicago, IL, USA, ENDO will bring together world-renowned speakers to showcase the latest developments in hormone science and medicine. Hear our president, Carol Lange, PhD, announce the distinguished plenary speakers and what they will be exploring at ENDO 2026. Learn more: https://bit.ly/4pknKyl Plenary sessions include: • Unraveling Hormonal Complexity: Genomics, Sex Differences, and Physiology • Metabolism in Motion: Endocrine Regulation as a Launchpad for Therapeutic Innovation • Molecular Mechanisms in Hormone Signaling: From Bench to Bedside

Our ENDO 2026 Plenary Lineup | We are excited to announce the ENDO Plenaries! Watch our president, Carol Lange, PhD, announce the distinguished plenary speakers and what they will be exploring at ENDO 2026: bit.ly/3MpRMlK #ENDO2026 #endocrinology #EndoSky

Call for Abstracts ENDO 2026 Call for Abstracts

#ENDO2026 Abstract Submitters: The deadline for our Outstanding Abstract Awards is Thursday, January 15. Select the Outstanding Abstract Awards option during abstract submission to apply. Learn more: https://bit.ly/49lxDqp #endocrinology

@cancercenteril.bsky.social @mcbillinois.bsky.social #BCSM

The latest paper from our group is now out! Extracelluar vesicles from neutrophils drive breast cancer cells towards being more stem-like; important consequences for chemotherapy. News story and summary here: cancer.illinois.edu/researchers-... . Publication found here: doi.org/10.1016/j.ca... .

And - a news story on the event here:
www.wcia.com/news/champai...

Register here:
forms.illinois.edu/sec/50084012...

More information on the Cancer Research Advocacy Group here, including links to previous webinars:
cancer.illinois.edu/cancer-resea...

Join the CCIL Cancer Research Advocacy Group for an online seminar focused on supporting mental health during a cancer diagnosis. Strategies for coping and finding empowerment through the journey - from an oncology counselor and survivors' perspectives. forms.illinois.edu/sec/50084012...

Gisella Carranza Leon, MD | ENDO 2026 Session Submissions Annual Meeting Steering Committee Chair (AMSC) Gisella Carranza Leon, MD, discusses how submitting a session idea can help you in your career. She also provides insight on how the AMSC uses session ideas to create ENDO programming. Submit your session suggestions and symposia proposals by Tuesday, September 2: https://bit.ly/4flCMjl #ENDO2026

Watch our videos with Annual Meeting Steering Committee Chair (AMSC) Gisella Carranza Leon, MD, on creation of ENDO programming and how submitting a session idea can help you in your career. She provides insight in English (bit.ly/3UOXNJB) and Español (bit.ly/47RuYUz). #ENDO2026 #endocrinology

What were your favorite articles in the current issue of @endocrinenews.bsky.social? Our cover story interviews Erik Nelson, PhD. Our features explore diabetes and liver disease and a Q&A C. Wayne Bardin International Travel Award Winner Yoshitomo Hoshino, MD, PhD. Read more: https://bit.ly/3UZMPkw

Help shape ENDO2026! Submit your suggestions for great endocrine society science now!

Sign for ENDO 2026 in Chicago.

Thanks for an amazing #ENDO2025! We will see you next year! @endocrinesociety.bsky.social #endosky

The Endocrine System Song by Peter Weatherall YouTube video by Peter Weatherall

@endocrinesociety.bsky.social #ENDO2025 rocking out to this beauty: youtu.be/KsBgcEvihS8?...

My amazing colleague @loriraetzman.bsky.social the 2025 Endoctrine Society Laureate Awardee for distinguished service. #ENDO2025 @endocrinesociety.bsky.social

Arrived at SFO #ENDO2025 @endocrinesociety.bsky.social

Some amazing programming about to happen at #ENDO2025 !! @endocrinesociety.bsky.social

Colorectal cancer treated with cholesterol inhibitor in U. of I. study | School of Molecular & Cellular Biology | Illinois University of Illinois researchers have successfully treated a common type of colorectal cancer tumor with a cholesterol inhibitor drug, demonstrating a promising treatment for the disease in animal experiments.

#Illinois researchers have successfully treated a common type of colorectal cancer tumor with a cholesterol inhibitor drug, demonstrating a promising treatment for the disease in animal experiments.

The study was published in Nature Chemical Biology:

go.mcb.illinois.edu/623
@nelsonlab.bsky.social

Research at Duke Restored Mei's Quality of Life YouTube video by Duke University

I am very proud to have helped develop Elacestrant for the treatment of breast cancer. There is still much to be done - and we show up to lab every day striving to do better for patients. Stories like these inspire us:
www.youtube.com/watch?v=Puk6...
#endcancer #BCSM #breastcancer #stage4

New review paper from the lab highlighting cholesterol, the immune system and tumor biology. PhD co-authors discuss its importance in this interview.

Just a day away! Join the Cancer Research Advocacy Group for a special webinar on survivorship. Great tips on navigating the insurance system!
Register here: forms.illinois.edu/sec/380306938

Screenshot of video of Brendan Harley - Why I study cancer

Why I Study Cancer

The cancers that are fatal today don't have to be tomorrow. Support for biomedical research enables generational shifts in how we treat cancer.

What a privilege to work at @cancercenteril. Work funded by National Institutes of Health

www.instagram.com/reel/DGTUxwD...